Share

January 29, 2013; 80 (5) Article

Cause-specific mortality of 1-year survivors of subarachnoid hemorrhage

Miikka Korja, Karri Silventoinen, Tiina Laatikainen, Pekka Jousilahti, Veikko Salomaa, Jaakko Kaprio
First published January 9, 2013, DOI: https://doi.org/10.1212/WNL.0b013e31827f0fb5
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
357

Share

Article Information

vol. 80 no. 5 481-486
DOI: 
https://doi.org/10.1212/WNL.0b013e31827f0fb5
PubMed: 
23303843
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received June 5, 2012
  • Accepted September 26, 2012
  • First Published January 9, 2013.

Article Versions

Copyright & Usage: 
© 2013 American Academy of Neurology

Author Disclosures

    1. Miikka Korja, MD, PhD,
    2. Karri Silventoinen, PhD,
    3. Tiina Laatikainen, MD, PhD,
    4. Pekka Jousilahti, MD, PhD,
    5. Veikko Salomaa, MD, PhD and
    6. Jaakko Kaprio, MD, PhD
  1. Miikka Korja, MD, PhD,
    2. Scientific Advisory Boards:

    1. (1) Dr. Miikka Korja has received honoraria from serving on the advisory board of Medtronic.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Study was supported by personal grants from the (1) Pro Humanitate Foundation, (2) Maire Taponen Foundation, (3) Emil Aaltonen Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Karri Silventoinen, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Tiina Laatikainen, MD, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Finnish Medical Journal, member of an editorial advisory board, 2008-2012

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. Academy of Finland, research funding, 2009-2013

    Research Support, Foundations and Societies:

    1. Juho Vainio foundation, research funding, 2011

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Pekka Jousilahti, MD, PhD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Veikko Salomaa, MD, PhD and
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. I have been serving as an associate editor of the European Journal of Cardiovascular Prevention and Rehabilitation for about 3 years.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. Academy of Finland, grant number 129494

    Research Support, Foundations and Societies:

    1. Finnish Foundation for Cardiovascular Research, and the Sigrid Juselius Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Jaakko Kaprio, MD, PhD
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. 1) Pfizer Ltd, speaker honorarium 2012

    Editorial Boards:

    1. Addiction, associate editor, 2008 - > Nicotine and Tobacco Research, associate editor, 2010 - > Twin Research and Human Genetics, editorial board member, 2003 -> Finnish Journal of Social Medicine 2000-> Psychiatric Genetics, editorial board member 2000->

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Pfizer Ltd, Pharmacogenetics of smoking cessation, 2011 & 2012

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1.  Addiction program (#118555, PI) 2007-2010 Academy of Finland, Centre of Excellence in Complex Disease Genetics, J.Kaprio group 2006-2011 Academy of Finland Finnish Distinguished Professor programme, co-host for Professor Joe Terwilliger (Columbia University) 2006-2010 Academy of Finland Finnish Distinguished Professor programme, host for Professor Juni Palmgren (Karolinska Institute) 2011-2015 Academy of Finland. Genes and environmental predictors of tobacco addiction in adolescents and young adults (PI). Consortium partner Olli Raitakari, University of Turku. Co-funded with CIHR (PI Rachel Tyndale, University of Toronto) . Funded through the SKIDI-Kids Research program. 2011-2014 European Union funding EC FP6. DiOGenes. Diet, Obesity and Genes. FP6-513946. J.Kaprio PI for University of Helsinki, http://www.diogenes-eu.org/ 2005-2009 EC FP7. TORNADO. Molecular Targets Open for Regulation by the gut flora - New Avenues for improved Diet to Optimize European health. KBBE-2007-2-2-07/222720-2 (JK PI for University of Helsinki partner, WP leader) Integrating project http://www.fp7tornado.eu/ 2009-2013 EC FP7. ENGAGE Consortium European Network for Genetic and Genomic Epidemiology. (HEALTH-F4-2007-201413). (JK PI University of Helsinki, University of Helsinki coordinator partner, JK WP leader). http://www.euengage.org/ Integrating project 2008-2012 EC FP7. GENODISC (Disc-degeneration linked pathologies: novel biomarkers and diagnostics for targeting treatment and repair). HEALTH-F2-2008-201626. 1.3.08-28.2.13. J.Kaprio PI for Helsinki partner and WP leader. (http://www.physiol.ox.ac.uk/genodisc/index.html) 2008-2013 EC FP7 I.Family. Determinants of eating behaviour in European children, adolescents and their parents-KBBE-2010-4. 2012-2017. J. Kaprio PI for University of Helsinki partner. 2012-2017 US NIH funding U.S. -P.H.S. (# DA-12584, yrs 6-10). Nicotine addiction genetics. Co-PI J.Kaprio. Finnish subcontract 2008-2012 U.S. -P.H.S. (# AA-12502) FinnTwin12 studies of alcohol use. Co-PI J.Kaprio. Finnish subcontract 2005-2010 U.S. -P.H.S. (# AA-15416, PI DM Dick) Gene-environment interactions in adolescent alcohol use. J.Kaprio Co-Investigator, 2005-2010 U.S.-P.H.S. (#AA-15416, PI DM Dick, Virginia Commonwealth University), supplemental award for genotyping 2009-2011 U.S.-P-H.S (# HL104125, Xiaoling Wang, Medical College of Georgia. A genome-wide methylation study on essential hypertension. (local PI J Kaprio) 2011-2016

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurosurgery (M.K.), Helsinki University Central Hospital, Helsinki; Population Research Unit (K.S.), Department of Social Research, University of Helsinki; Departments of Chronic Disease Prevention (T.L., P.J., V.S.) and Mental Health and Substance Abuse Services (J.K.), National Institute for Health and Welfare, Helsinki; The Institute of Public Health and Clinical Nutrition (T.L.), University of Eastern Finland, Kuopio; Hospital District of North Karelia (T.L.), Joensuu; Department of Public Health (J.K.), University of Helsinki; and Institute for Molecular Medicine FIMM (J.K.), Helsinki, Finland.
  1. Correspondence to Dr. Korja: miikka.korja{at}hus.fi
View Full Text

Article usage

Article usage: January 2013 to April 2020

AbstractFullPdfSource
Jan 201310861345Highwire
Feb 20138441831Highwire
Mar 2013229912Highwire
Apr 201310898Highwire
May 201310447Highwire
Jun 20136167Highwire
Jul 20135013Highwire
Aug 20134401Highwire
Sep 20135702Highwire
Oct 20133804Highwire
Nov 20133925Highwire
Dec 20133401Highwire
Jan 20144652Highwire
Feb 20143200Highwire
Mar 20143611Highwire
Apr 20143811Highwire
May 20142801Highwire
Jun 20142701Highwire
Jul 20143013Highwire
Aug 20143014Highwire
Sep 20142800Highwire
Oct 20142200Highwire
Nov 20141712Highwire
Dec 20142911Highwire
Jan 20152000Highwire
Jan 2015042pmc
Feb 20151002Highwire
Feb 2015063pmc
Mar 20152716Highwire
Mar 20150918pmc
Apr 20151300Highwire
Apr 2015054pmc
May 20151200Highwire
May 2015084pmc
Jun 20152200Highwire
Jun 2015074pmc
Jul 20152200Highwire
Jul 2015083pmc
Aug 20151500Highwire
Aug 2015082pmc
Sep 20151611Highwire
Sep 2015054pmc
Oct 20151310Highwire
Oct 20150116pmc
Nov 20152411Highwire
Nov 2015043pmc
Dec 20151800Highwire
Dec 2015054pmc
Jan 20161911Highwire
Jan 2016031pmc
Feb 20163013Highwire
Feb 2016042pmc
Mar 20161400Highwire
Mar 2016031pmc
Apr 20161721Highwire
Apr 2016022pmc
May 20161600Highwire
May 2016063pmc
Jun 20161200Highwire
Jun 2016042pmc
Jul 20161001Highwire
Jul 2016063pmc
Aug 20164210Highwire
Aug 2016065pmc
Sep 20168602Highwire
Sep 2016035pmc
Oct 20163312Highwire
Oct 2016051pmc
Nov 20163310Highwire
Nov 2016022pmc
Dec 20162821Highwire
Dec 2016011pmc
Jan 20172000Highwire
Jan 2017074pmc
Feb 20171400Highwire
Feb 2017043pmc
Mar 20172210Highwire
Mar 2017071pmc
Apr 20176000Highwire
Apr 2017377pmc
May 20171400Highwire
May 20174910pmc
Jun 20172011Highwire
Jul 20171310Highwire
Jul 2017222pmc
Aug 2017900Highwire
Aug 2017266pmc
Sep 20171200Highwire
Sep 2017146pmc
Oct 2017710Highwire
Oct 2017577pmc
Nov 20171631Highwire
Nov 2017233pmc
Dec 20172301Highwire
Jan 20182410Highwire
Feb 20181001Highwire
Mar 20181611Highwire
Apr 20182223Highwire
Apr 2018156pmc
May 20183111Highwire
Jun 20183123Highwire
Jun 2018299pmc
Jul 20182801Highwire
Aug 20181901Highwire
Aug 201811413pmc
Sep 20181301Highwire
Oct 20182403Highwire
Nov 20181630Highwire
Dec 20181633Highwire
Jan 20191610Highwire
Feb 20191610Highwire
Mar 20192702Highwire
Apr 20191402Highwire
May 20192102Highwire
Jun 20191001Highwire
Jul 20191010Highwire
Aug 20191310Highwire
Sep 20191151Highwire
Oct 20191730Highwire
Nov 20191701Highwire
Dec 20191601Highwire
Jan 20201620Highwire
Feb 20201211Highwire
Mar 2020900Highwire
Apr 20201460Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me